Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of KPCXM18 in Healthy Subjects
NCT04629287Phase 1Unknown
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing KPCXM18 for injection with Placebo (2 arms). Primary endpoints: Number of subjects with abnormal vital signs up to 2 weeks, Number of subjects with abnormal laboratory values up to 2 weeks and 3 more. Status: unknown.
02
Drugs
ginsenotriol disuccinate sodium
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04629287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629287.